New Zealand markets open in 5 hours 37 minutes

Clearmind Medicine Inc. (CMND)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.0600+0.0400 (+3.92%)
As of 12:12PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.0200
Open1.0200
Bid1.0200 x 100
Ask1.1200 x 100
Day's range1.0112 - 1.1100
52-week range0.9210 - 20.4000
Volume178,176
Avg. volume1,085,428
Market cap3.457M
Beta (5Y monthly)-1.66
PE ratio (TTM)N/A
EPS (TTM)-6.8900
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink

    Vancouver, Canada, June 11, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces advancement in its proprietary MEAI- based alcohol substitute beverage program. The Company previously announced the initiation of the last pre-clinical study required for a novel-food applicatio

  • GlobeNewswire

    Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product

    The global market of no- and low-alcohol beverages estimated at over $13 billion in 2023 Vancouver, Canada, May 10, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces advancement in its proprietary MEAI- based alcohol substitute beverage program. The Company has completed m

  • GlobeNewswire

    Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment

    Vancouver, Canada, May 07, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces the signing of an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This agreement provides Clearmind with exclusive global right